Adeno-Associated Virus Gene Therapy for Liver Disease

Area of Science:

• * Molecular Medicine
• * Genetics and Genomics
• * Hepatology

Background:

• * Adeno-associated virus (AAV) gene therapy has seen significant advancements in the last decade.
• * Development of novel capsid serotypes and organ-specific promoters has improved efficacy.
• * Understanding of immune responses to AAV vectors is crucial for therapeutic success.

Purpose of the Study:

• * To review the progress of liver-directed AAV gene therapy.
• * To discuss current challenges and future directions in the field.
• * To provide historical context for AAV gene therapy targeting liver disorders.

Main Methods:

• * Literature review of published studies and clinical trials.
• * Analysis of advancements in AAV vector technology and immunology.
• * Synthesis of information on liver-specific gene therapy applications.

Main Results:

• * Liver-directed AAV gene therapy has shown remarkable progress.
• * Numerous clinical trials are underway for hemophilia A and B, and other liver diseases.
• * Novel serotypes and promoters enhance targeting and reduce immunogenicity.

Conclusions:

• * Liver-directed AAV gene therapy holds significant promise for treating genetic liver disorders.
• * Overcoming challenges related to immunogenicity and delivery is key for future development.
• * Continued research will expand the therapeutic applications of AAV gene therapy in hepatology.